{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T09:28:26Z","timestamp":1761989306354,"version":"3.37.3"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,2,11]],"date-time":"2019-02-11T00:00:00Z","timestamp":1549843200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Fujian Education & Scientific Research Project for Young Scholars","award":["JA14140S"],"award-info":[{"award-number":["JA14140S"]}]},{"DOI":"10.13039\/100001547","name":"China Medical Board","doi-asserted-by":"publisher","award":["11-067"],"award-info":[{"award-number":["11-067"]}],"id":[{"id":"10.13039\/100001547","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["71704026"],"award-info":[{"award-number":["71704026"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12913-019-3937-0","type":"journal-article","created":{"date-parts":[[2019,2,11]],"date-time":"2019-02-11T07:05:19Z","timestamp":1549868719000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Evidence for the effectiveness of anti-hypertensive medicines included on the Chinese National Reimbursement Drug List"],"prefix":"10.1186","volume":"19","author":[{"given":"Wenbin","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lizheng","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monika","family":"Sawhney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoli","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingyao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,2,11]]},"reference":[{"key":"3937_CR1","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1377\/hlthaff.23.1.124","volume":"23","author":"PJ Neumann","year":"2004","unstructured":"Neumann PJ. Evidence-based and value-based formulary guidelines. Health Aff. 2004;23:124\u201334.","journal-title":"Health Aff"},{"key":"3937_CR2","first-page":"2977","volume":"22","author":"Y Yang","year":"2011","unstructured":"Yang Y, He P, Zou Y, Wang H, Wu Z. GRADE method and the application of it in the selection of essential drugs by WHO. China Pharm. 2011;22:2977\u201380.","journal-title":"China Pharm"},{"key":"3937_CR3","volume-title":"The selection and use of essential medicines: report of the WHO expert committee","author":"World Health Organization","year":"2015","unstructured":"World Health Organization. The selection and use of essential medicines: report of the WHO expert committee. Geneva: World Health Organization; 2015."},{"key":"3937_CR4","first-page":"1453","volume":"21","author":"L Wang","year":"2010","unstructured":"Wang L, Yuan Q, Cheng L, Li Y. Reflection on the selection and evaluation of essential drug list. China Pharm. 2010;21:1453\u20136.","journal-title":"China Pharm"},{"key":"3937_CR5","first-page":"3","volume":"4","author":"L Fan","year":"2011","unstructured":"Fan L, Ma A. Discussion on the related questions about basic drug list selection. Health Economics Res. 2011;4:3\u20136.","journal-title":"Health Economics Res"},{"key":"3937_CR6","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1186\/1472-6963-12-401","volume":"12","author":"X Tian","year":"2012","unstructured":"Tian X, Song Y, Zhang X. National Essential Medicine List and policy practice: a case study of China's health care reform. BMC Health Serv Res. 2012;12:401.","journal-title":"BMC Health Serv Res"},{"key":"3937_CR7","first-page":"353","volume":"27","author":"Y Guo","year":"2013","unstructured":"Guo Y, Gan L, Xing H, Yuan HM. Analysis on the successful experience of selecting essential drugs in the other countries. Chinese Pharm Aff. 2013;27:353\u20135.","journal-title":"Chinese Pharm Aff"},{"key":"3937_CR8","first-page":"68","volume":"12","author":"Y Huang","year":"2013","unstructured":"Huang Y, Guo Y. Comparisons of the management models of domestic and foreign medical insurance covered medicine catalogs. Chinese Med Insur. 2013;12:68\u201370.","journal-title":"Chinese Med Insur"},{"key":"3937_CR9","volume-title":"WHO model list of essential medicines (20th list)","author":"World Health Organization","year":"2017","unstructured":"World Health Organization. WHO model list of essential medicines (20th list). 2017. \n                    http:\/\/www.who.int\/medicines\/publications\/essentialmedicines\/en\/\n                    \n                  . Assessed 22 May, 2017."},{"key":"3937_CR10","doi-asserted-by":"publisher","first-page":"15","DOI":"10.4103\/0189-7969.201909","volume":"14","author":"U OgbaJoseph","year":"2017","unstructured":"OgbaJoseph U, IheanyiDamian E. The eighth joint national committee on the prevention, detection, evaluation, and treatment of high blood pressure (joint national committee-8) report: Matters arising. Nigerian J Cardiol. 2017;14:15. \n                    https:\/\/doi.org\/10.4103\/0189-7969.201909\n                    \n                  .","journal-title":"Nigerian J Cardiol"},{"key":"3937_CR11","volume-title":"Hypertension: Clinical Management of Primary Hypertension in Adults. NICE Clinical Guideline 127","author":"National Institute for Health and Clinical Excellence","year":"2011","unstructured":"National Institute for Health and Clinical Excellence. Hypertension: Clinical Management of Primary Hypertension in Adults. NICE Clinical Guideline 127. London: National Clinical Guideline Centre; 2011."},{"issue":"6","key":"3937_CR12","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. The PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med. 2009;6(6):e1000097.","journal-title":"PLoS Med."},{"key":"3937_CR13","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/1471-2288-7-10","volume":"7","author":"BJ Shea","year":"2007","unstructured":"Shea BJ, Grimshaw JM, Wells GA, et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Med Res Methodol. 2007;7:10.","journal-title":"BMC Med Res Methodol"},{"key":"3937_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","volume":"17","author":"AR Jadad","year":"1996","unstructured":"Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1\u201312.","journal-title":"Control Clin Trials"},{"key":"3937_CR15","first-page":"3372","volume":"25","author":"X Zeng","year":"2014","unstructured":"Zeng X, Liu J, Chen J, et al. Efficacy and safety of Fosinopril for mild to moderate essential hypertension: a systematic review. China Pharm. 2014;25:3372\u20136.","journal-title":"China Pharm"},{"issue":"3","key":"3937_CR16","first-page":"259","volume":"17","author":"J Gasowski","year":"2010","unstructured":"Gasowski J, Wilkins A, Drzewoski J, et al. Short-term antihypertensive efficacy of perindopril according to clinical profile of 3,188 patients: a meta-analysis. Cardiol J. 2010;17(3):259\u201366.","journal-title":"Cardiol J"},{"key":"3937_CR17","first-page":"961","volume":"9","author":"S Chen","year":"2015","unstructured":"Chen S, Wang JJ, Wang QQ, et al. The effect of carvedilol and propranolol on portal hypertension in patients with cirrhosis: a meta-analysis. Patient Prefer Adherence. 2015;9:961\u201370.","journal-title":"Patient Prefer Adherence"},{"key":"3937_CR18","first-page":"28","volume":"36","author":"Z Ke","year":"2015","unstructured":"Ke Z, Yao R, Chen Z, Fang C. Meta-analysis of the therapeutic efficacy and safety of doxazosin for mild to moderate essential hypertension. J Kunming Med Univ. 2015;36:28\u201332.","journal-title":"J Kunming Med Univ"},{"key":"3937_CR19","first-page":"735","volume":"14","author":"X Zhou","year":"2016","unstructured":"Zhou X, Ma W. Efficacy of Urapidil in treatment for heart failure with hypertension: a Meta-analysis. Chinese J Cardiovasc Res. 2016;14:735\u20138.","journal-title":"Chinese J Cardiovasc Res"},{"key":"3937_CR20","first-page":"125","volume":"15","author":"S Li","year":"2012","unstructured":"Li S, Qin L, Xu G. Effect of domestic Cilnidipine in the treatment of essential hypertension: a Meta analysis. Chinese Gen Pract. 2012;15:125\u20137.","journal-title":"Chinese Gen Pract"},{"key":"3937_CR21","first-page":"3778","volume":"23","author":"W Dong","year":"2012","unstructured":"Dong W, Huang T, Zhou Y, Dong Y. Effects of sodium nitroprusside in the treatment of hypertensive emergency: a systematic review. China Pharm. 2012;23:3778\u201382.","journal-title":"China Pharm"},{"key":"3937_CR22","first-page":"111","volume":"6","author":"Q Hua","year":"2014","unstructured":"Hua Q. Meta-analysis of Lacidipine and amlodipine for essential hypertension. Front Med China. 2014;6:111\u20138.","journal-title":"Front Med China"},{"key":"3937_CR23","first-page":"245","volume":"10","author":"C Jiang","year":"2013","unstructured":"Jiang C, Qiu J, Xu Y, et al. Meta analysis on Nicardipine in the treatment of hypertensive emergency. Chinese J Drug Appl Monit. 2013;10:245\u201350.","journal-title":"Chinese J Drug Appl Monit"},{"key":"3937_CR24","first-page":"4980","volume":"44","author":"Y Ran","year":"2015","unstructured":"Ran Y, Wei L, Li D, Kuang F, Zhao C, Qian Y. The efficacy and tolerability of Lercanidipine and amlodipine for mild to moderate hypertension: Meta-analysis. Chongqing Med. 2015;44:4980\u20134.","journal-title":"Chongqing Med"},{"key":"3937_CR25","first-page":"949","volume":"35","author":"B Du","year":"2009","unstructured":"Du B, Qin L, Cui W. Meta analysis on Arotinolol in treatment of essential hypertension. J Jilin Univ. 2009;35:949\u201354.","journal-title":"J Jilin Univ"},{"key":"3937_CR26","first-page":"2524","volume":"26","author":"S Zhao","year":"2015","unstructured":"Zhao S, Yang W, Chen B. Meta-analysis of the efficacy and safety of benazepril vs. captopril in the treatment of primary hypertension. China Pharm. 2015;26:2524\u20136.","journal-title":"China Pharm"},{"key":"3937_CR27","first-page":"54","volume":"55","author":"Y Zhang","year":"2015","unstructured":"Zhang Y, Shou S, Liu Y, Wang L. The efficacy of Enopril folic acid in treatment of H type hypertension. Shandong Med. 2015;55:54\u20136.","journal-title":"Shandong Med"},{"key":"3937_CR28","first-page":"517","volume":"37","author":"H Wu","year":"2011","unstructured":"Wu H, Xu G, Qin L. Meta-analysis on effectiveness and safety of irbesarten\/hydrochlorothiazide combination therapy in treatment of essential hypertension. J Jilin Univ (Medicine Edition). 2011;37:517\u201322.","journal-title":"J Jilin Univ (Medicine Edition)"},{"key":"3937_CR29","first-page":"394","volume":"32","author":"J Jin","year":"2013","unstructured":"Jin J, Yue Y, Jin Z, Wu F. Efficacy and safety of valsartan hydrochlorothiazide for primary hypertension: a Meta-analysis. Herald Med. 2013;32:394\u20137.","journal-title":"Herald Med"},{"key":"3937_CR30","first-page":"318","volume":"15","author":"Z Zhao","year":"2015","unstructured":"Zhao Z, Chen Y. Efficacy and safety of amlodipine vs. Levamlodipine for mild to moderate hypertension: a systematic review. Eval Anal Drug-Use Hosp China. 2015;15:318\u201321.","journal-title":"Eval Anal Drug-Use Hosp China"},{"key":"3937_CR31","first-page":"332","volume":"41","author":"Q Chen","year":"2014","unstructured":"Chen Q, Ding D, Qin J. Efficacy of nimodipine combined with edaravone in treatment of hypertensive intracerebral hemorrhage: a meta-analysis. J Int Neurol Neurosurg. 2014;41:332\u20137.","journal-title":"J Int Neurol Neurosurg"},{"key":"3937_CR32","first-page":"245","volume":"13","author":"Y Wu","year":"2009","unstructured":"Wu Y, He L, Song Y, Hu Y. Compound anti-hypertensive tablets (no.0) for primary hypertension: a systematic review. China J Dis Control Prev. 2009;13:245\u201350.","journal-title":"China J Dis Control Prev"},{"issue":"3","key":"3937_CR33","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1517\/14740338.2015.998197","volume":"14","author":"LA Magee","year":"2015","unstructured":"Magee LA, Namouz-Haddad S, Cao V, Koren G, Von DP. Labetalol for hypertension in pregnancy. Expert Opin Drug Saf. 2015;14(3):453\u201361.","journal-title":"Expert Opin Drug Saf"},{"key":"3937_CR34","first-page":"3219","volume":"23","author":"L Hu","year":"2012","unstructured":"Hu L, Liu S. Efficacy and safety of compound reserpine tablets for essential hypertension: systematic review. China Pharm. 2012;23:3219\u201323.","journal-title":"China Pharm"},{"issue":"1","key":"3937_CR35","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2165\/11208210-000000000-00000","volume":"72","author":"KP Garnockjones","year":"2012","unstructured":"Garnockjones KP. Esmolol: a review of its use in the short-term treatment of tachyarrhythmias and the short-term control of tachycardia and hypertension. Drugs. 2012;72(1):109\u201332.","journal-title":"Drugs"},{"key":"3937_CR36","first-page":"59","volume":"34","author":"X Du","year":"2014","unstructured":"Du X, Yin X, Zhang X. Comprehensive evaluation on amlodipine and Nitrendipine therapy for hypertension. Chin Hosp Pharm J. 2014;34:59\u201362.","journal-title":"Chin Hosp Pharm J"},{"key":"3937_CR37","first-page":"37","volume":"21","author":"T Zhang","year":"2013","unstructured":"Zhang T, Wang X, Fan Q, Chen H, Hu Y. Efficacy and safety of amlodipine and Felodipine in the treatment of Chinese hypertension. PJCCPVD. 2013;21:37\u201340.","journal-title":"PJCCPVD"},{"issue":"8","key":"3937_CR38","first-page":"CD004934","volume":"65","author":"MR Kandler","year":"2010","unstructured":"Kandler MR, Mah GT, Tejani AM, Stabler SN, Salzwedel DM. Hydralazine for essential hypertension. Cochrane Database Syst Rev. 2010;65(8):CD004934.","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"3937_CR39","first-page":"CD007655","volume":"202","author":"SD Shamon","year":"2009","unstructured":"Shamon SD, Perez MI. Blood pressure lowering efficacy of reserpine for primary hypertension. Cochrane Database Syst Rev. 2009;202(4):CD007655.","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"3937_CR40","first-page":"1013","volume":"34","author":"J Cao","year":"2012","unstructured":"Cao J, Lei J, Gong T, Li L, Chen G, Chen W. Antihypertensive efficacy of amlodipine benapril in the treatment of mild to moderate hypertension: a randomized controlled trial. Hebei Med J. 2012;34(7):1013\u20134.","journal-title":"Hebei Med J"},{"issue":"21","key":"3937_CR41","first-page":"5","volume":"3","author":"N Lu","year":"2006","unstructured":"Lu N, Lu K, Zhuang W, Xiang Q, Zhong Y, Ling J. The effectiveness and safety in treating unstable angina by metoprolol: a randomized controlled trial. Med Ind Inf. 2006;3(21):5\u20137.","journal-title":"Med Ind Inf"},{"issue":"5","key":"3937_CR42","first-page":"342","volume":"12","author":"W Zuo","year":"2007","unstructured":"Zuo W, Wang C, Xue X. Porspective study on the effects of drug intervention is preventing the first bleeding of esophageal varices: a randomize controlled trial with propranolol, ISMN and spironolactone in combination. Chinese Hepatol. 2007;12(5):342\u20135.","journal-title":"Chinese Hepatol"},{"issue":"2","key":"3937_CR43","first-page":"90","volume":"6","author":"X Jiang","year":"2001","unstructured":"Jiang X, Wang J, Chen S, Zhu C. A randomized controlled clinical trial in the prevention of esophageal variceal bleeding. Chin J Gastroenterol. 2001;6(2):90\u20133.","journal-title":"Chin J Gastroenterol"},{"issue":"8","key":"3937_CR44","first-page":"680","volume":"24","author":"G Huang","year":"2008","unstructured":"Huang G, Jia J, Zhen Y, et al. Multicentric prospective randomized controlled study of efficacy of mannitol, furosemide and albumin in reducing intracranial pressure in patients with severe brain injury. Chin J Trauma. 2008;24(8):680\u20133.","journal-title":"Chin J Trauma"},{"issue":"6","key":"3937_CR45","first-page":"699","volume":"13","author":"W Zheng","year":"2008","unstructured":"Zheng W, Cao Y. Clinical randomized controlled trial on torasemide injection in treating patients with congestive heart failure and edema. Chin J Clin Pharmacol Ther. 2008;13(6):699\u2013703.","journal-title":"Chin J Clin Pharmacol Ther"},{"issue":"1","key":"3937_CR46","first-page":"1","volume":"9","author":"Q Lu","year":"2000","unstructured":"Lu Q, Zhao M, Rong Y, Liu X. Random case-control study of the effectiveness of Naftopidil and terazosin in treatment of hypertension. Chin J Pharmacoepidemiol. 2000;9(1):1\u20133.","journal-title":"Chin J Pharmacoepidemiol"},{"issue":"4B","key":"3937_CR47","first-page":"48","volume":"7","author":"Y Liao","year":"2014","unstructured":"Liao Y. Randomized controlled trial on the efficacy of Olmesartan Medoxomil in remodeling left ventricular in treatment of morning surge of hypertension. Chin J Clin Ration Drug Use. 2014;7(4B):48\u20139.","journal-title":"Chin J Clin Ration Drug Use"},{"key":"3937_CR48","first-page":"550","volume":"15","author":"B Tao","year":"2006","unstructured":"Tao B, Guo J, Chen S, et al. Comparison of two combination regimens in the treatment of mild to moderate essential hypertension. Chinese J New Drugs. 2006;15:550\u20133.","journal-title":"Chinese J New Drugs"},{"issue":"11","key":"3937_CR49","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1517\/14656566.6.11.1911","volume":"6","author":"MJ Rokoss","year":"2005","unstructured":"Rokoss MJ, Teo KK. Ramipril in the treatment of vascular diseases. Expert Opin Pharmacother. 2005;6(11):1911\u20139.","journal-title":"Expert Opin Pharmacother"},{"key":"3937_CR50","first-page":"884","volume":"24","author":"X Jiang","year":"2005","unstructured":"Jiang X, Zhang Y, Wang R, et al. Comparison of imidapril and benazepril on central and peripheral blood pressures through pulse wave analysis. Chin J New Drugs Clin Rem. 2005;24:884\u20136.","journal-title":"Chin J New Drugs Clin Rem."},{"key":"3937_CR51","first-page":"238","volume":"33","author":"Collaborative Group of Diltiazem","year":"2005","unstructured":"Collaborative Group of Diltiazem. A multicenter, randomized clinical trial of intravenous diltiazem in treatment of unstable angina. Chin J Cardiol. 2005;33:238\u201342.","journal-title":"Chin J Cardiol"},{"key":"3937_CR52","first-page":"759","volume":"25","author":"X Wang","year":"2006","unstructured":"Wang X, Ke Y, Wu W, Zhou X, Jiang S. Efficacy of combination of enalapril\/hydrochlorothiazide in Chinese patients with primary hypertension. Chin J New Drugs Clin Rem. 2006;25:759\u201362.","journal-title":"Chin J New Drugs Clin Rem"},{"issue":"S1","key":"3937_CR53","first-page":"16","volume":"86","author":"EL Schiffrin","year":"2008","unstructured":"Schiffrin EL. Remodeling of resistance arteries in human hypertension: effects of Cilazapril, an angiotensin-I-converting enzyme inhibitor. Cardiology. 2008;86(S1):16\u201322.","journal-title":"Cardiology"},{"key":"3937_CR54","first-page":"1447","volume":"15","author":"Y Li","year":"2015","unstructured":"Li Y, Yu J, Du L, et al. Exploration and practice of methods and processes of evidence-based rapid review on peer review of WHO EML application. Chin J Evid Based Med. 2015;15:1447\u201353.","journal-title":"Chin J Evid Based Med"},{"issue":"Suppl 1","key":"3937_CR55","doi-asserted-by":"publisher","first-page":"S202","DOI":"10.1017\/S0266462309090643","volume":"25","author":"Y Chen","year":"2009","unstructured":"Chen Y, Banta D, Tang Z. Health technology assessment development in China. Int J Technol Assess Health Care. 2009;25(Suppl 1):S202\u20139.","journal-title":"Int J Technol Assess Health Care"},{"key":"3937_CR56","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1017\/S0266462314000737","volume":"30","author":"W Liu","year":"2014","unstructured":"Liu W, Shi L, Pong RW, et al. Differences in evaluating health technology assessment knowledge translation by researchers and policy-makers in China. Int J Technol Assess Health Care. 2014;30:612\u201320.","journal-title":"Int J Technol Assess Health Care"},{"key":"3937_CR57","first-page":"226","volume":"29","author":"M Cui","year":"2011","unstructured":"Cui M, Peng Y, Zhao J, Fang T. Comparative study of the health insurance directory entrance procedure of new drug domestic and overseas and the suggestion on the relevant policy in China. J Pharm Pract. 2011;29:226\u20138.","journal-title":"J Pharm Pract"},{"key":"3937_CR58","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.2165\/00019053-200624110-00011","volume":"24","author":"A Laupacis","year":"2006","unstructured":"Laupacis A. Economic evaluations in the Canadian common drug review. Pharmacoeconomics. 2006;24:1157.","journal-title":"Pharmacoeconomics"},{"key":"3937_CR59","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1377\/hlthaff.22.1.125","volume":"22","author":"N Daniels","year":"2003","unstructured":"Daniels N, Teagarden JR, Sabin JE. An ethical template for pharmacy benefits. Health Aff. 2003;22:125.","journal-title":"Health Aff"}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-019-3937-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12913-019-3937-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-019-3937-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,10]],"date-time":"2020-02-10T19:10:32Z","timestamp":1581361832000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmchealthservres.biomedcentral.com\/articles\/10.1186\/s12913-019-3937-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,11]]},"references-count":59,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["3937"],"URL":"https:\/\/doi.org\/10.1186\/s12913-019-3937-0","relation":{},"ISSN":["1472-6963"],"issn-type":[{"type":"electronic","value":"1472-6963"}],"subject":[],"published":{"date-parts":[[2019,2,11]]},"assertion":[{"value":"24 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The research does not report on or involve the use of any animal or human data or tissue. Therefore, the ethics approval and consent to participate are not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"112"}}